Welcome to our dedicated page for Polyrizon SEC filings (Ticker: PLRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Polyrizon Ltd. (PLRZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Polyrizon files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, and these documents offer insight into its development-stage biotechnology activities, financial condition, and corporate actions.
Recent Form 6-K filings incorporate press releases on key scientific and product milestones, such as preclinical results for PL-14 Allergy Blocker and PL-16 Viral Blocker, as well as data from the company’s intranasal naloxone hydrogel program within the Trap & Target™ platform. Other 6-K submissions include interim condensed financial statements, management’s discussion and analysis, and notices related to shareholder meetings and voting matters.
Filings also document capital structure and listing-related events. For example, Polyrizon has reported a reverse share split of its ordinary shares at a 1-for-6 ratio and has furnished a press release noting that it regained compliance with Nasdaq listing requirements. These disclosures help investors understand changes in share count, adjustments to warrants and options, and the company’s listing status.
Through Stock Titan, users can review Polyrizon’s 6-K reports and related exhibits, including financial statements, regulatory correspondence summaries, and scientific press releases that are incorporated by reference into registration statements on Form S-8 and Form F-3. AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting key sections on topics such as product development, regulatory interactions with the FDA, and corporate approvals, helping readers navigate Polyrizon’s SEC reporting history more efficiently.
Polyrizon Ltd. furnished a Form 6-K that attaches a press release titled “Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation.”
The filing states that the first four paragraphs of this press release are incorporated by reference into the company’s Registration Statements on Form S-8, to be part of those registrations from the date this report is submitted, to the extent not superseded by later filings.
Polyrizon Ltd. furnished a Form 6-K as a foreign private issuer, providing a press release dated October 6, 2025. The release is titled “Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy,” indicating that PL-14 showed encouraging allergen-blocking performance in pre-clinical testing. The first five paragraphs of this press release are expressly incorporated by reference into Polyrizon’s effective employee equity Registration Statements on Form S-8, making the scientific update part of those registration statements from the date of this filing.
Polyrizon Ltd., a foreign private issuer based in Israel, filed a Form 6-K reporting that it has furnished a press release titled “Polyrizon Submits Pre-Sub Package to the FDA for PL-14 Allergy Blocker.” This indicates the company has initiated a formal pre-submission interaction with the U.S. Food and Drug Administration regarding its PL-14 Allergy Blocker product. The first two paragraphs of this press release are incorporated by reference into Polyrizon’s existing employee equity Registration Statements on Form S-8, making that information part of those registration statements from the date of this report, unless later superseded.
Polyrizon Ltd. has submitted a Form 6-K as a foreign private issuer, furnishing its interim condensed financial statements as of June 30, 2025 and related notes. The report also includes management’s discussion and analysis of financial condition and results of operations for the six months ended June 30, 2025.
Certain exhibits to this Form 6-K are incorporated by reference into Polyrizon’s existing Form S-8 registration statements, meaning the updated financial and narrative information becomes part of those employee equity plan registrations from the submission date.
Polyrizon Ltd. reports that its shareholders approved all proposals presented at a special general meeting held on September 4, 2025. The proposals were approved by the required majorities under Israeli Companies Law and the company’s amended and restated articles of association, as previously described in the proxy materials sent to shareholders.
This report on Form 6-K is also being incorporated by reference into Polyrizon’s existing Form S-8 registration statements, so that the information in this report becomes part of those filings for securities issued under the company’s equity compensation plans.
Polyrizon Ltd. submitted a Form 6-K reporting that it has furnished a press release titled “Polyrizon Regains Compliance with Nasdaq Listing Requirements.”
The company notes that the first three paragraphs of this press release are incorporated by reference into its existing Form S-8 registration statements, meaning those equity compensation-related registrations now formally include this compliance update.